Company / Cost of Revenue
OCULAR THERAPEUTIX, INC Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.6M
FY2025
5-year range
$2.1M / $6.6M
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#72 of 85
Health Care
What the data says
OCULAR THERAPEUTIX, INC's cost of revenue of $7M is lower than 85% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 3 consecutive years, from $2M in FY2022 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +23.1%.
Increased from $5M to $7M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +46.7%
- 5-Year CAGR
- +23.1%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 85This company $6.6M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +23.1%, indicating consistent growth.
- In FY2025, cost of revenue increased 16.9% year-over-year.
- Ranks #72 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.6M | +16.9% |
| FY2024 | $5.6M | +6.5% |
| FY2023 | $5.3M | +153.5% |
| FY2022 | $2.1M | -10.4% |
| FY2021 | $2.3M | +0.0% |
| FY2020 | $2.3M | +408.8% |
| FY2019 | $457.0K | -1.7% |
| FY2018 | $465.0K | +1.8% |
| FY2017 | $457.0K | +3.2% |
| FY2016 | $443.0K | +386.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026